Somalogic Inc
F:76X0
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Somalogic Inc
SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company is headquartered in New York City, New York and currently employs 320 full-time employees. The company went IPO on 2021-02-23. The company develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein. The company offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaSignal Tests, SomaScan Panels, and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. SomaSignal Tests are available as laboratory developed tests (LDT) for use in obtaining proteomics information from patients and monitoring patients’ physiological states, among others. SomaScan Panels consists of two categories: fixed panels and custom panels. The company offers drug development, analysis of clinical trial and new human biology insights.
SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company is headquartered in New York City, New York and currently employs 320 full-time employees. The company went IPO on 2021-02-23. The company develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein. The company offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaSignal Tests, SomaScan Panels, and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. SomaSignal Tests are available as laboratory developed tests (LDT) for use in obtaining proteomics information from patients and monitoring patients’ physiological states, among others. SomaScan Panels consists of two categories: fixed panels and custom panels. The company offers drug development, analysis of clinical trial and new human biology insights.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
